Aryan Kadivar, MD
Family Medicine · Lawton, OKNPI 1578509170
Payments from drug & device makers
Across 677 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$1K
- AstraZeneca$940
- Merck$936
- Novartis$684
- Pfizer$540
- plus $7K from 54 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$11,76798%
- Education$2782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,045 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 411 | $375,721 |
| OzempicSemaglutide | 201 | $263,465 |
| EntrestoSacubitril/Valsartan | 213 | $192,357 |
| MounjaroTirzepatide | 124 | $147,977 |
| EliquisApixaban | 148 | $110,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $67,796 |
| FarxigaDapagliflozin Propanediol | 55 | $58,697 |
| TrulicityDulaglutide | 47 | $52,597 |
| MyrbetriqMirabegron | 71 | $43,513 |
| LinzessLinaclotide | 49 | $43,363 |
| VascepaIcosapent Ethyl | 89 | $40,193 |
| XareltoRivaroxaban | 49 | $39,412 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $27,085 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $25,705 |
| KerendiaFinerenone | 34 | $23,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $435 | $409,775448 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $535 | $285,288233 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,084 | $200,574171 claims |
| NovartisEntresto | $684 | $192,357213 claims |
| PfizerEliquis | $540 | $110,577148 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $299 | $77,70785 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $940 | $74,830100 claims |
| Astellas Pharma US IncMyrbetriq | $332 | $43,51371 claims |
| AbbVieLinzess | $447 | $43,36349 claims |
| Johnson & JohnsonXarelto | $132 | $39,41249 claims |
| MerckVerquvo, Belsomra | $936 | $25,18137 claims |
| BayerKerendia | $284 | $23,26934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Lawton
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.